Related Experiment Video
Updated: Jul 6, 2026

An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants
Published on: May 22, 2020
Lecanemab: More Questions Than Answers!
Upinder Kaur1, Jaideep Reddy2, Ashutosh Tiwari3
1Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
Lecanemab, a new Alzheimer's drug, targets amyloid beta but offers minimal cognitive benefits. Its approval faces controversy due to safety concerns and potential risks, prompting further analysis of its efficacy.
Area of Science:
- Neurology
- Pharmacology
- Biochemistry
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- Amyloid beta plaques are a key pathological hallmark of AD.
- Current AD treatments offer limited symptomatic relief.
Purpose of the Study:
- To analyze the evidence supporting lecanemab as an anti-amyloid beta therapy for Alzheimer's disease.
- To discuss the concerns regarding the clinical relevance of lecanemab's cognitive benefits.
- To evaluate the safety profile and adverse events associated with lecanemab treatment.
Main Methods:
- Review of phase III clinical trial data for lecanemab.
- Analysis of amyloid-related imaging abnormalities (ARIA) and other adverse events.
- Assessment of statistical significance versus clinical relevance of cognitive improvements.
Main Results:
- Lecanemab demonstrated statistically significant cognitive benefits in phase III trials.
- Cognitive improvements were minimal, raising questions about clinical relevance.
- Adverse events, including ARIA and participant deaths, were reported.
Conclusions:
- Lecanemab represents a novel therapeutic approach targeting amyloid beta in AD.
- The clinical significance of lecanemab's benefits requires careful consideration.
- Ongoing monitoring and further research are crucial to understand lecanemab's long-term efficacy and safety.
More Related Videos
07:17A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
Published on: January 29, 2021
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
Related Concept Videos
Fundamental Attribution Error
Blank Solutions
In some experimental cases, the reagents, solvents, or lab equipment used in...
Castigliano's Theorem: Problem Solving
Problem-Solving
Introspection
Gaussian Elimination: Problem Solving